Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Nov;142(11):1087-92.
doi: 10.1001/archsurg.142.11.1087.

Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer

Affiliations

Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer

Peter Kornprat et al. Arch Surg. 2007 Nov.

Abstract

Hypothesis: Thermoablation, either cryosurgical ablation (CSA) or radiofrequency ablation (RFA), combined with resection is effective in the treatment of extensive bilobar colorectal metastasis.

Design: Retrospective analysis of a prospective hepatobiliary surgical database.

Setting: Tertiary care referral center.

Patients: Consecutive patients with colorectal hepatic metastases selected for surgical treatment.

Interventions: All patients underwent hepatic resection combined with CSA or RFA.

Main outcome measures: Local recurrence rates at ablation sites, overall survival, disease-free survival, and hepatic disease-free survival.

Results: Between January 1, 1998, and December 31, 2003, 665 patients with colorectal metastases underwent hepatic resection. Of these, 39 (5.9%) had additional intraoperative thermoablative procedures (19 RFA, 20 CSA). There was 1 (3%) postoperative death not directly associated with the ablation, and the total morbidity rate was 41% (16 of 39). No RFA-related complication occurred; however, 3 patients developed an abscess at cryoablation sites. Actuarial 3-year survival was 47% for the entire group, with a median follow-up of 21.1 months (range, 0.5-71.4 months). The median disease-free survival was 12.3 months (range, 8.4-16.2 months). Overall, the local in situ recurrence rate according to number of ablated tumors was 14% for RFA and 12% for CSA. Tumor size correlated directly with recurrence (P = .02) in RFA-treated lesions.

Conclusions: Ablation combined with hepatic resection is rarely necessary or applicable. However, in selected patients whose tumors were otherwise unresectable, additional use of ablation allows effective clearance of disease. In these patients with extensive bilobar disease, recurrence rates are high, but long-term survival is encouraging and may be improved with aggressive postoperative chemotherapy.

PubMed Disclaimer